The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy

Ophthalmology

Volumn 108, Issue 12, 2001, Pages 2266-2272

  Beck, Roy W ^a   Frank, Robert N ^a   Kraker, Ray T ^a   Ellis, Katrina J ^a  

^a JAEB CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE RECEPTOR; GROWTH HORMONE RECEPTOR ANTAGONIST; HORMONE RECEPTOR BLOCKING AGENT; PEGVISOMANT; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE COURSE; DOSE RESPONSE; DRUG SELF ADMINISTRATION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPHTHALMOSCOPY; PRIORITY JOURNAL; REMISSION; RETINA NEOVASCULARIZATION; TREATMENT PLANNING;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DRUG EVALUATION; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, SOMATOTROPIN; TREATMENT OUTCOME;

EID: 0035191536     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(01)00853-3     Document Type: Article

References (32)

1. The Houssay phenomenon in man: Recovery from retinopathy in a case of diabetes with Simmond's disease
2. Diabetes and anterior pituitary insufficiency: Final course and postmortem study of a diabetic patient with Sheehan's syndrome
3. The treatment of diabetic retinopathy by pituitary implantation of radioactive yttrium
4. Hypophysectomy for diabetic angiopathy: A controlled clinical trial
5. Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy
6. Florid diabetic retinopathy and its response to treatment by photocoagulation or pituitary ablation
7. Growth hormone, insulin-like growth factors and diabetes
8. Diabetic retinopathy
9. 90
10. Serum growth hormone levels and the response of diabetic retinopathy to pituitary ablation
11. A follow-up study of vascular disease in growth-hormone-deficient dwarfs with diabetes
12. The role of growth hormone in the development of diabetic retinopathy
13. Human growth hormone stimulates proliferation of human retinal microvascular endothelial cells in vitro
14. Failure to suppress GH secretion after 2 weeks treatment with atropine or propantheline in diabetics with proliferative retinopathy
15. Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy
16. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus
17. Growth hormone suppression and nonproliferative diabetic retinopathy: A preliminary feasibility study
18. Elevation of serum IGF-I precedes proliferative diabetic retinopathy in Mauriac's syndrome
19. Why some cases of retinopathy worsen when diabetic control improves
20. Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization
21. Essential role of growth hormone in ischemia-induced retinal neovascularization
22. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice
23. Rational design of potent antagonists to the human growth hormone receptor
24. Long-acting growth hormones produced by conjugation with polyethylene glycol
25. PEG-modified proteins
26. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
27. Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study
28. Grading diabetic retinopathy from stereoscopic color fundus photographs - An extension of the modified Airlie House classification. ETDRS Report Number 10
29. Proliferative diabetic retinopathy
30. Energy metabolism and substrate oxidation in acromegaly
31. Insulin resistance in acromegaly: Defects in both hepatic and extrahepatic insulin action
32. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes